Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of CCX168 in ANCA-associated vasculitis
NL-OMON41237Phase 2Active, not recruiting
- Sponsor
- ChemoCentryx
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and 1 more comparing CCX168 plus background therapy with Placebo plus background therapy (2 arms). Primary endpoints: Safety and tolerability of CCX168 and Efficacy by Birmingham Vasculitis Activity Score version 3. Started Apr 2013; status: active, not recruiting.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)renal limited vasculitis (RLV)
Beyond the preview
Go deeper on NL-OMON41237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41237.